We notice that either EGFR TKI or RAPGEF3 inhibitor alone has marginal inhibitory effect on tumor growth, whereas the antitumor effect is dramatically enhanced upon combinational therapy in RAPGEF3high tumors. The gene discussed is EGFR; the disease is neoplasm.